Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
It is known as the hepatic manifestation of metabolic syndrome, primarily because insulin resistance appears to be one of the main physiological mechanisms causing intra- and perihepatic fat accumulation. The prevalence of non-alcoholic fatty liver disease ranges from 3% to 36.9% in the general population. It is more prevalent in patients in their fourth to sixth decades of life, of male gender, Hispanic ethnicity, or those with metabolic syndrome.
Associated risk factors include: Obesity in 80%, abnormal blood lipid levels (dyslipidemia) in 65%, glucose intolerance and/or diabetes mellitus in 75%, and systemic arterial hypertension. The disease is asymptomatic in most patients, although some may experience pain in the upper right abdomen, fatigue, and symptoms typical of the associated conditions such as diabetes, hypertension, and dyslipidemia. The management of non-alcoholic fatty liver disease consists of treating not only the liver condition but also its associated metabolic disorders, including obesity, dyslipidemia, diabetes mellitus, insulin resistance, or any alteration in carbohydrate metabolism.
For more information and to rule out this pathology, request your consultation today.
